spot_img
10.2 C
London
HomeInvestors HealthSummit Therapeutics gains on cancer trial data (SMMT:NASDAQ)

Summit Therapeutics gains on cancer trial data (SMMT:NASDAQ)

BOMAR ENT.
By BOMAR ENT.


Cancer cells vis

koto_feja

Summit Therapeutics (NASDAQ:SMMT) traded higher for the fifth straight session on Thursday as investors continued to cheer the latest trial data for its lead asset, ivonescimab, which indicated an outperformance against tislelizumab, a PD-1 inhibitor marketed by BeiGene (



Source link

Previous article
Stock Market Invest Day Trader Trading Candlestick Finance Gifts Financial Securities Gaming Keyboard Mouse Pad Mousepad Desk Mat Huge Extended XL Stitched Rubber Sole for Home Office(31.5″X 11.8″)
Next article
Retirement Income Source: The Ultimate Guide to Eternal Income
Investors Health Image

latest articles

explore more

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Important Disclosure:
As an Amazon Associate I earn from qualifying purchases.

most viewed

trending right now

Copyright © INVESTORS HEALTH - BOMAR GROUP

FAQ

Contact us